The landscape of global healthcare reached a significant milestone this October as the Evidence Based Health Care (EBHC) 2026 Conference convened in the historic city of Taormina, Italy, bringing together a prestigious assembly of medical professionals, researchers, and policy architects. Held from October 21 to 24, the event served as a critical nexus for the advancement of clinical methodologies, with the Endocrine Society maintaining a prominent presence throughout the four-day summit. Representing the Society’s leadership in clinical excellence were Roma Gianchandani, MD, Chair of the Clinical Guidelines Committee, and Christopher R. McCartney, MD, a member of the Endocrine Society Board of Directors and a primary Guideline Methodologist. They were joined by the Society’s professional staff, including Maureen Corrigan, MPH, Director of Evidence Based Practice, and Katie Delaney, Program Manager of Evidence Based Practice, underscoring the organization’s commitment to the rigorous application of scientific data in patient care.
The conference was structured as a landmark joint meeting, merging the 11th EBHC International Conference with the 11th Conference of the International Society for Evidence-Based Health Care (ISEHC). This dual-platform approach allowed for a comprehensive exploration of the digital transformation currently sweeping through the medical research community. Central to the discussions was the burgeoning role of artificial intelligence (AI) and automated digital tools in reshaping how medical evidence is generated, synthesized, and eventually translated into clinical practice guidelines (CPGs).
The Strategic Role of the Endocrine Society
The participation of the Endocrine Society in Taormina highlights the organization’s ongoing effort to remain at the forefront of medical standardization. As the largest global organization representing specialists in endocrinology and the broader field of hormone research, the Society’s guidelines influence the treatment protocols for millions of patients worldwide suffering from conditions such as diabetes, thyroid disorders, and osteoporosis.
Dr. Roma Gianchandani and Dr. Christopher McCartney provided essential perspectives on the practical challenges of maintaining guideline integrity in an era of rapid scientific output. The presence of Maureen Corrigan and Katie Delaney further emphasized the operational side of evidence-based practice—specifically, the complex methodology required to filter thousands of peer-reviewed studies into actionable clinical recommendations. According to Delaney, the Society’s involvement in the international evidence community is not merely participatory; it is a strategic necessity. She noted that engaging with global experts keeps the Society’s methodology aligned with evolving international standards and ensures that they play a proactive role in shaping the future of guideline development.
The AI Revolution in Evidence-Based Healthcare
One of the primary themes of EBHC 2026 was the "digital revolution" and its impact on the lifecycle of medical evidence. Traditionally, the process of developing a clinical practice guideline is a multi-year endeavor. It involves defining clinical questions, conducting exhaustive systematic reviews of existing literature, grading the quality of evidence, and reaching a consensus among experts. However, the sheer volume of medical research published annually has made the traditional manual model increasingly difficult to sustain.
Data presented at the conference suggested that the volume of medical literature is doubling approximately every 73 days in some specialties. For organizations like the Endocrine Society, this creates a significant "knowledge-to-action" gap. AI tools discussed at the conference offer a potential solution by automating the initial stages of literature screening and data extraction. Natural Language Processing (NLP) models are now being trained to identify high-quality randomized controlled trials (RCTs) with greater speed and accuracy than manual human screening, allowing experts to focus their energy on the interpretation of results rather than the tedious collection of data.
Transitioning to Living Guidelines
A major focus of the Taormina sessions was the shift toward "living guidelines." Unlike traditional guidelines, which may be updated only every five to ten years, living guidelines are designed to be updated as close to real-time as possible. This approach is particularly relevant in fast-moving fields such as oncology and endocrinology, where new drug approvals and clinical trial results can change the "standard of care" almost overnight.
The EBHC 2026 delegates discussed the technical infrastructure required to support these dynamic updates. This includes the use of digital platforms that allow for "modular" guideline updates. Instead of revising an entire 100-page document, organizations can update specific recommendations within the document as new evidence becomes available. This ensures that clinicians have access to the most current information without waiting years for a formal republication.
The Endocrine Society’s methodology team has been exploring these "living" models to ensure that their clinical practice guidelines remain the gold standard for practitioners. By utilizing digital tools to monitor new research as it is indexed in databases like PubMed or Embase, the Society can maintain a "constant state of readiness" to adjust clinical recommendations.
Background Context and Global Significance
The EBHC conference series has long been regarded as the premier gathering for the International Society for Evidence-Based Health Care. The choice of Taormina, Italy, for the 2026 meeting provided a symbolic backdrop—a city known for its ancient history serving as the venue for discussions on the future of high-tech medicine.
The International Society for Evidence-Based Health Care (ISEHC) was founded on the principle that healthcare decisions should be based on the best available, current, valid, and relevant evidence. Since its inception, the organization has worked to bridge the gap between academic research and bedside application. The 2026 joint meeting represented a culmination of a decade of growth in the field of evidence synthesis, moving beyond the "what" of evidence-based medicine to the "how" of digital delivery.
The conference chronology included specialized tracks for guideline developers, systematic reviewers, and clinical educators. Early sessions focused on the "Ethics of AI," addressing concerns regarding bias in algorithms and the importance of maintaining human oversight in clinical decision-making. Mid-conference workshops allowed organizations like the Endocrine Society to share their specific workflows, fostering a cross-pollination of ideas between different medical specialties.
Supporting Data: The Efficiency of Digital Tools
Supporting research discussed at the conference highlighted the efficiency gains provided by the digital transformation. In a pilot study reviewed during the sessions, researchers found that AI-assisted screening reduced the time required for systematic reviews by up to 30% without compromising the sensitivity of the search. For a professional society, this reduction in administrative burden translates to faster delivery of guidelines to the medical community.
Furthermore, statistics on "guideline adherence" were a point of concern for many delegates. Studies indicate that even when high-quality guidelines are published, it can take years for them to be fully integrated into primary care. The digital tools showcased at EBHC 2026 aim to solve this by integrating guidelines directly into Electronic Health Records (EHRs). By embedding Society recommendations into the digital tools doctors use daily, the "evidence" becomes a seamless part of the clinical workflow rather than a separate document that must be sought out.
Broader Impact and Future Implications
The implications of the EBHC 2026 Conference extend far beyond the walls of the meeting halls in Taormina. As the Endocrine Society and its international peers adopt these new methodologies, the global medical community can expect a more agile and responsive healthcare system.
The shift toward AI-driven evidence synthesis also raises important questions about global equity in healthcare. Experts at the conference emphasized that while digital tools can speed up research in high-income countries, the methodology must remain adaptable to low-resource settings. The Endocrine Society’s commitment to global standards ensures that their guidelines are not only technologically advanced but also culturally and economically relevant to a diverse international audience.
Looking forward, the insights gained from EBHC 2026 will likely inform the Endocrine Society’s strategic plan for the next decade. The integration of AI and the move toward living guidelines represent a fundamental shift in the "social contract" between medical societies and their members. Clinicians no longer just look to societies for occasional updates; they look for a constant stream of verified, high-quality information that can help them navigate the complexities of modern patient care.
As the conference concluded on October 24, the consensus among the attendees was clear: the era of static, paper-based medical evidence is coming to an end. The work of the Endocrine Society’s representatives in Taormina ensures that the field of endocrinology will not only keep pace with this digital evolution but will serve as a leading voice in defining the new standards of evidence-based practice for the 21st century.
For those seeking more detailed information on the proceedings and the ongoing work of the International Society for Evidence-Based Health Care, resources are available through the official conference portal at ebhcconference.org. The Endocrine Society continues to build upon the connections and methodologies established in Taormina, reinforcing its role as a cornerstone of clinical excellence in the global medical community.
